BIO-TECHNE Corp vs Vital Farms Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Vital Farms Inc trades at $9.45 (market cap $396.69M). The key difference: BIO-TECHNE Corp is far larger — about 28.7× Vital Farms Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vital Farms Inc for 14 Days on average.
| TECH | VITL | |
|---|---|---|
Market Cap | $11.37B | $396.69M |
Volume | 3,153,511 | 1,219,207 |
Sector | Health | Consumer Staples |
52-Week High | $72.61 | $43.68 |
52-Week Low | $43.31 | $8.28 |
Typical Hold Time | 63 Days | 14 Days |
Enterprise Value | $11.40B | $483.70M |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, amid a bearish technical signal and challenging fundamentals. Recent earnings show volatility with a Q2 2026 loss of $0.47 per share, though it slightly beat expectations, while revenue declined 10% year-over-year in that quarter. The company faces pressure from egg pricing and oversupply, as noted in recent news, but maintains a 'Buy' consensus from analysts with a $13.11 price target.
The outlook is mixed: strong analyst support and potential strategic options like a sale offer upside, but weak profitability margins and cash flow concerns pose significant risks. Investors should weigh the company's market position against ongoing industry headwinds and execution challenges in the near term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →